High-Dose Oral Insulin Fails to Prevent Islet Autoimmunity: Primary Results from the POInT Randomized Trial

High-Dose Oral Insulin and the Quest for Primary Prevention

Type 1 diabetes (T1D) remains one of the most challenging chronic conditions of childhood, characterized by the autoimmune destruction of insulin-producing pancreatic beta cells. For decades, the medical community has sought a ‘holy grail’ in pediatric endocrinology: a way to prevent the autoimmune process before it begins. The Primary Oral Insulin Trial (POInT), a large-scale, European, multicenter, randomized, placebo-controlled trial, recently published in The Lancet, investigated whether the early introduction of oral insulin could induce immunological tolerance and prevent the development of islet autoimmunity in genetically predisposed infants.

Highlights